Ana de Barros, PhD, managing science editor —

Ana holds a PhD in immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. Ana was awarded two FCT fellowships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon.

Articles by Ana de Barros

AdAlta and Crossbeta Enter Alzheimer’s Disease-Specific Shark Antibodies Agreement

AdAlta and Crossbeta Biosciences have entered into a commercialization agreement, granting Crossbeta with a license to three beta-amyloid oligomer (AßO)-specific shark antibodies, considered to have disease-specific potential for the diagnosis and treatment of Alzheimer’s disease (AD). These three shark antibodies were identified under a December 2013 agreement between…

BrightStar Care Offering Q&A Sessions, ‘Connections’ Campaign for Alzheimer’s Awareness Month

BrightStar Care, a national at-home senior care franchise, has launched an Alzheimer’s awareness campaign — Memories and Connections — for Alzheimer’s Awareness Month. The campaign is designed to equip family or care partners with information, educational tips, and activities to create meaningful connections with loved ones living with Alzheimer’s…

Startups Collaborate with Galaxy in New Effort to Increase Alzheimer’s Patient Participation in Research

Roobirk and Antidote, two startup companies that work to empower people living with Alzheimer’s disease have entered a partnership with Galaxy, an online portal to initiatives that facilitate patient participation in Alzheimer’s research. More than 80% of clinical studies overall are delayed or closed because not enough patients meet enrollment requirements.

vTv Therapeutics to Detail Potential Alzheimer’s Treatment, Now in Phase 3 Study, at Meeting Today

Larry Altstiel, MD, PhD, chief medical officer of vTv Therapeutics, will speak today on the panel “Novel Approaches to Alzheimer’s Disease,” during the Neuro Advance Boston conference hosted by Harvard Medical School. Altstiel will detail the mechanisms of action of azeliragon, vTv Therapeutics’ investigative treatment for mild Alzheimer’s disease…